CervoMed (CRVO) Total Current Liabilities (2010 - 2025)
CervoMed (CRVO) posted Total Current Liabilities of $4.7 million for Q4 2025, up 4442.07% sequentially from $102511.0 in Q1 2025, and up 20.03% YoY from $3.9 million in Q4 2024.
CervoMed (CRVO) Total Current Liabilities (2010 - 2025) Analysis & Trends
CervoMed has reported Total Current Liabilities for 16 years, with the latest figure at $4.7 million in Q4 2025.
- Quarterly Total Current Liabilities rose 20.03% year-over-year to $4.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.7 million (up 20.03% YoY) and the FY2025 annual result came in at $4.7 million, up 20.03% from the prior year.
- Total Current Liabilities climbed to $4.7 million in Q4 2025 per CRVO's latest filing, from $102511.0 in the prior quarter.
- Over five years, Total Current Liabilities peaked at $4.7 million in Q4 2025 and troughed at $50322.0 in Q4 2022.
- A 5-year average of $941758.2 and a median of $99973.0 in 2023 frame the typical range for Total Current Liabilities.
- The widest YoY moves for Total Current Liabilities: up 17151.7% in 2021, down 97.29% in 2021.
- Over 5 years, Total Current Liabilities stood at $65935.0 in 2021, then slipped by 23.68% to $50322.0 in 2022, then soared by 76.18% to $88659.0 in 2023, then jumped by 4275.51% to $3.9 million in 2024, then advanced by 20.03% to $4.7 million in 2025.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $4.7 million, $102511.0, and $3.9 million for Q4 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | CervoMed | 26.12 Mn | 26.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.66 Mn |
| Mar 31, 2025 | 102,511.00 |
| Dec 31, 2024 | 3.88 Mn |
| Sep 30, 2024 | 98,672.00 |
| Jun 30, 2024 | 116,818.00 |
| Mar 31, 2024 | 63,806.00 |
| Dec 31, 2023 | 88,659.00 |
| Sep 30, 2023 | 121,501.00 |
| Jun 30, 2023 | 58,268.00 |
| Mar 31, 2023 | 101,274.00 |
| Dec 31, 2022 | 50,322.00 |
| Sep 30, 2022 | 2.27 Mn |
| Jun 30, 2022 | 77,744.00 |
| Mar 31, 2022 | 2.96 Mn |
| Dec 31, 2021 | 65,935.00 |
| Sep 30, 2021 | 88,485.00 |
| Jun 30, 2021 | 2.10 Mn |
| Mar 31, 2021 | 55,205.00 |
| Dec 31, 2020 | 2.44 Mn |
| Sep 30, 2020 | 2.69 Mn |